SAN FRANCISCO, September 23 /PRNewswire/ -- InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the Israeli MGuard(TM) Registry. MGuard(TM) was successfully implanted in Natanya, Israel, at the Laniado Hospital Cath Lab, managed by Dr. Yitzhak Herz, the principal investigator for the Registry at this hospital.
The Israeli MGuard Registry will enroll 100 'real world' MGuard patients from eight hospitals in Israel. Data from the registry will be used to support data from other MGuard clinical studies.
The first MGuard Stent in the Israeli MGuard Registry was implanted by Dr. Guy Schoenmann from the Laniado Hospital in Netanya. The patient was a 70 year old male treated for myocardial infarction (MI) caused by a thrombus occluding the right coronary artery. Dr. Schoenmann stated: "MGuard(TM) was delivered with no complications and it immediately enabled excellent flow in the artery. We experienced a very successful procedure and I am very pleased that MGuard is now available to us on daily basis".
Mr. Eli Bar CTO and VP R&D stated: "Currently MGuard is mostly used in AMI, SVG, and thrombus containing lesions. The Israeli MGuard registry is very important for us in order to understand the clinical performance of MGuard in the 'real world' and receive a wider perspective on its use in special patient subgroups".
On September 24th 2009, InspireMD will Sponsor a Breakfast Meeting at the
TCT Conference 2009 in San Francisco, Titled "The Role of the MGuard(TM)
Stent in Thrombus Management During AMI Interventions". The meeting chairman
will be Dr. Martin B. Leon , the Chairman of the CRF, NY; Associate Director
at New York Presbyterian Hospital and Professor at
About MGuard(TM) Coronary
MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The protective sleeve is composed of a micron-level-fiber which is knit in order to ensure flexibility while retaining the strength characteristics of the fiber material. The sleeve is designed to expand seamlessly when the stent is deployed, without affecting the structural integrity of the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without complicating deliverability. Reduced injury to the vessel as a result of diffused stent pressure is a benefit of the sleeve which may lead to lower risk of restenosis. MGuard(TM) is CE Mark approved.
The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.
InspireMD Ltd. is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis.
In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures. For further information visit http://www.inspire-md.com
Contact: Jonina Ohayon Marketing Director Tel +972-52-5791120 firstname.lastname@example.org
Copyright©2009 PR Newswire.
All rights reserved